It was found that 4 out of 106 serious and severe patients in Korea who received the Corona19 treatment'Remdesivir' had an adverse reaction.

Kwon Joon-wook, deputy general manager of the Central Defense Response Headquarters (4th), at the regular briefing held at the Osong Disease Control Headquarters in Chungbuk Province, reported about 4 cases of adverse reactions when he saw the status of the (dose) administration of the remedyvir. "The side effects are a slight increase in liver levels, hives on the skin, rashes, and a slight premature contraction of the ventricles in the heart," he said.

He said, "Severe and severe patients with remedyvir treatment usually have a high age group and many high-risk patients with underlying disease." "The remedyvir effect is being further reviewed with clinical experts."

The government introduced Remedyvir to Korea through the'Special Imports' procedure, and began supplying it on the 1st of last month, and has given Remedyvir to 108 serious and seriously ill patients in 33 hospitals to date.

Patients who can receive Lemdesivir are seriously ill with pneumonia, who are receiving oxygen therapy, and have had symptoms within 10 days.

The dosing is based on 6 bottles of 10 ml injections for 5 days, but the dosing period can be extended by 5 days if necessary.

Remedyvir is an antiviral drug developed by Gilead Sciences in the United States for the treatment of Ebola, and has been confirmed to have a corona19 treatment effect, and is being imported as a remedy worldwide.